Gufic Biosciences targets to capture major share of Rs 3000 crore lyophilized antibacterial market in India

07 Jun 2022 Evaluate

Gufic Biosciences has targeted to capture major share of Rs 3000 crore lyophilized antibacterial market in India. Gufic has launched New Drug Delivery System: Dual Chamber Bags at affordable price for the first time in India.

Contributing immensely to the government's ambitious Make in India drive, Gufic has collaborated with its European counterpart to manufacture this new technology indigenously in India. Until now the dual chamber bags have been largely imported in India at a very high cost to the patients. On the contrary, Gufic has not only launched high-quality Dual Chamber Bags at an affordable and pocket friendly price, these New Drug Delivery System products even have longer shelf -life.

Gufic Biosciences is engaged in diversified business viz. Pharma, Healthcare, Bio- Technology, Seeds, Herbal etc.

Gufic Biosciences Share Price

321.80 -4.40 (-1.35%)
15-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1528.20
Dr. Reddys Lab 5872.35
Cipla 1405.95
Zydus Lifesciences 997.45
Lupin 1638.40
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.